Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-carnitine and Piracetam in Postpoliomyelitis Syndrome
NCT01549847Phase 3Withdrawn
- Sponsor
- Biolab Farmacêutica
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-polio syndrome (PPS) comparing L-carnitine and piracetam with Placebo (2 arms). Primary endpoints: Changes in Muscle Weakness at 26 weeks and Changes in fatigue at 26 weeks. Status: withdrawn.
02
Drugs
levocarnitinepiracetam
03
Conditions
post-polio syndrome (PPS)
Beyond the preview
Go deeper on NCT01549847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01549847.